Lenvatinib
- BNF:
- Immune system and malignant disease
- Status:
- Red
- Decision Date:
- None
Comments
RED:
- NICE TA498 Lenvatinib with everolimus for previously treated advanced renal cell carcinoma (decision date - February 2018)
- NICE TA535 - Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine (decision date - September 2018
- NICE TA551: for untreated advanced hepatocellular carcinoma (decision date - January 2019)
- NICE TA858 - Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma. NHSE commissioned. (Decision date - February 2023)
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
- 8. NHS England commissioned – to be used in line with NHSE commissioning intentions
search again